Standard BioTools to Announce Second Quarter 2026 Financial Results on August 5, 2026

Standard BioTools to Announce Second Quarter 2026 Financial Results on August 5, 2026

Standard BioTools Inc. (NASDAQ: LAB) today announced that it will publish its second quarter 2026 financial results on Wednesday, August 5, 2026, after U.S. market close.About Standard BioTools Inc.

Standard BioTools, Inc. (NASDAQ: LAB), is committed to setting the new standard in the life science tools industry through strategic consolidation, best-in-class operations and a world-class management team. The Company's established portfolio includes essential, standardized next-generation solutions designed to help biomedical researchers develop better therapeutics faster.

For Research Use Only. Not for use in diagnostic procedures.

Limited Use Label License and other terms may apply: standardbio.com/legal/terms-and-conditions/.
Patent and License Information: standardbio.com/legal/notices.

Trademarks: standardbio.com/legal/trademarks. Any other trademarks are the sole property of their respective owners. ©2026 Standard BioTools Inc. (f.k.a. Fluidigm Corporation). All rights reserved.

Standard BioTools products are provided for Research Use Only. Not for use in diagnostic procedures.

Investor Contact:
ir@standardbio.com


Primary Logo

News Provided by GlobeNewswire via QuoteMedia

Standard BioToolsLABNGS:LABbiotech investing
LAB
The Conversation (0)
Brixton Metals Samples New Vein Grading 195 g/t Gold, 4.11% Copper and 147 g/t Silver At Its Thorn Project

Brixton Metals Samples New Vein Grading 195 g/t Gold, 4.11% Copper and 147 g/t Silver At Its Thorn Project

Brixton Metals Corporation (TSX-V: BBB, OTCQX: BBBXF) (the "Company" or "Brixton") is pleased to announce that it has identified a new high-grade gold-copper-silver vein at the Golden Valley Target. This new target is located 17 kilometers south-southeast of its Trapper Gold Target and 24... Keep Reading...
Renforth Extends Surface Gold Mineralization In Channels On Wholly Owned Parbec Gold Deposit In Malartic, Quebec

Renforth Extends Surface Gold Mineralization In Channels On Wholly Owned Parbec Gold Deposit In Malartic, Quebec

(TheNewswire) 6.20 g/t Au over 0.50m within 2.93 g/t Au over 1.70m in CHNL-PAR-26-59, the highest grade among the new channel results received for Parbec. 28.77 g/t Au over 0.60m within 8.02 g/t Au over 2.55m in CHNL-PAR-26-58 (previously reported), the highest grade returned to date in the 2026... Keep Reading...
Standard Uranium Initiates Partner Funded Surface Exploration Program at the Corvo Uranium Project, Eastern Athabasca Basin, Saskatchewan

Standard Uranium Initiates Partner Funded Surface Exploration Program at the Corvo Uranium Project, Eastern Athabasca Basin, Saskatchewan

Standard Uranium Ltd. (TSXV: STND,OTC:STTDF) (OTCQB: STTDF) (FSE: 9SU0) ("Standard Uranium" or the "Company") is pleased to announce the commencement of additional ground exploration on its Corvo Uranium Project ("Corvo", or the "Project"), currently under a three-year earn-in option agreement... Keep Reading...
Brixton Metals Drills 4 m of 1,975 g/t Silver within 23.50 m of 348 g/t Silver in Hole 449 at its Langis Project in Ontario

Brixton Metals Drills 4 m of 1,975 g/t Silver within 23.50 m of 348 g/t Silver in Hole 449 at its Langis Project in Ontario

And 6.45 m of 667 g/t Silver, Including 3.19 m of 1,339 g/t Silver In Hole 412 And 9.00 m of 222 g/t Silver, Including 0.50 m of 1,605 g/t Silver In Hole 442 Brixton Metals Corporation (TSX-V: BBB, OTCQX: BBBXF) (the "Company" or "Brixton") is pleased to report silver results from 28 holes at... Keep Reading...
Marvel Biosciences Signs Letter of Intent with Novatech for Phase 1 Trial of MB-204 and Provides Corporate Update

Marvel Biosciences Signs Letter of Intent with Novatech for Phase 1 Trial of MB-204 and Provides Corporate Update

Marvel Biosciences Corp. (TSXV: MRVL,OTC:MBCOF | OTCQB: MBCOF), and its wholly-owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), a drug discovery company developing novel therapeutics for autism spectrum disorder ("ASD") and related neurodevelopmental... Keep Reading...
Lexaria Announces Results from Animal Study GLP-1-A26-1

Lexaria Announces Results from Animal Study GLP-1-A26-1

KELOWNA, BC / ACCESS Newswire / October 15, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to provide the following results from animal study GLP-1-A26-1 (the "Study") that evaluated a number of formulation... Keep Reading...
Lexaria Announces Results From Animal Study GLP-1-A26-1

Lexaria Announces Results From Animal Study GLP-1-A26-1

(TheNewswire) Results highlighted by a 566% improvement in brain absorption of DehydraTECH-CBD Kelowna, BC October 15, 2026 TheNewswire - Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to provide the following... Keep Reading...
GLP-1 Weight-Loss/Diabetes Industries Continue Transition to Oral Medications

GLP-1 Weight-Loss/Diabetes Industries Continue Transition to Oral Medications

KELOWNA, BC / ACCESS Newswire / October 6, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is providing this strategic update.Lexaria's DehydraTECHâ„¢ technology is currently being evaluated both by Lexaria and... Keep Reading...
BriaCell Therapeutics (TSX:BCT)

BriaCell’s Bria-ABC Joins Roster of US-Enrolled Breast Cancer Trials

BriaCell Therapeutics’ (TSX:BCT,NASDAQ:BCTX) Phase 3 Bria-ABC study has been included in a roundup of breast cancer clinical trials currently enrolling in the US, published by cancer publication CURE.In its September 24 article, CURE enumerated seven studies spanning early-stage to heavily... Keep Reading...
Lexaria Updates Financial Position

Lexaria Updates Financial Position

KELOWNA, BC / ACCESS Newswire / September 17, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is providing the following update.Lexaria is in a strong cash position following both its recently announced Australian tax... Keep Reading...
Lexaria Announces Closing of Exercise of Warrants for Approximately $5.9 Million in Gross Proceeds

Lexaria Announces Closing of Exercise of Warrants for Approximately $5.9 Million in Gross Proceeds

KELOWNA, BC / ACCESS Newswire / September 9, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today closed its previously announced exercise of certain outstanding warrants to purchase an aggregate of 453,969 shares of the... Keep Reading...

Latest News

More News

Interactive Chart

Latest Press Releases

Canadian Investment Regulatory Organization Trade Resumption - PBF

Precious Metals & Critical Minerals Virtual Investor Conference Presentations Now Available for On-Demand Viewing

Steadright Private Placement Upsized to $900K and Appoints Director

CoTec Holdings Corp. Announces Final Closing of Private Placement of Unsecured Convertible Debentures, Total Raise of $20 Million

Related News

lithium investing

Top 5 Canadian Mining Stocks This Week: Lithium Africa Rises Over 50 Percent on Assay Results

uranium investing

Uranium American, DISA Partner to Recover Uranium Waste

precious metals investing

Precious Metals & Critical Minerals Virtual Investor Conference Presentations Now Available for On-Demand Viewing

base metals investing

Steadright Private Placement Upsized to $900K and Appoints Director

base metals investing

CoTec Holdings Corp. Announces Final Closing of Private Placement of Unsecured Convertible Debentures, Total Raise of $20 Million

precious metals investing

Aurum hits gold outside BST1 resource ahead of MRE update

gold investing

Dr. Mark Thornton: Gold, Silver's Next Leg — This "Engine" to Drive Prices?